Home › Drug Codes › Q Codes › Q2055 · Abecma
Updated July 1st, 2026

Abecma Q Code: Q2055

Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for Q2055, effective October 1, 2026: $575,850.465 per HCPCS billing unit, up 1.4% from $567,977.78. From CMS's final file.

?
Medicare Payment Limit ?
$567,977.78
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$567,977.78
/ HCPCS billing unit · APC 9422
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
3
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
HCPCS Added Date January 1, 2022
Manufacturer Celgene
Route of Administration Intravenous
Generic Status Single-Source; Branded
Dosage Form Suspension

About Abecma

Abecma is a medication aligned to the HCPCS Q Code: Q2055 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the intravenous route and manufactured by Celgene.

According to CMS Drug Use Information: Idecabtagene vicleucel is used to treat a certain type of cancer (multiple myeloma) that has not gotten better or that has come back after other kinds of treatment. This type of treatment is known as gene therapy. Idecabtagene vicleucel is made from your own white blood cells and is given only to you. The white blood cells have been changed to have a specific protein (chimeric antigen receptor-CAR) that helps your body slow or stop the growth of certain cancer cells.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
59572-0515-01 Abecma Celgene Corporation 1 Abecma Intravenous Sus pension 30000000… Login for More
59572-0515-02 Abecma Celgene Corporation 1 Abecma Intravenous Sus pension 30000000… Login for More
59572-0515-03 Abecma Celgene Corporation 1 Abecma Intravenous Sus pension 30000000… Login for More
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

Abecma Pricing & Reimbursement

Q2055 Private Payer Reimbursement
$591,666.59 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

Abecma Claims Performance

Claims from Jan 2026 – Aug 2026
Claim Denial Rate 50%
Avg. Days to File 2.0days
Avg. Days to Pay 48.0days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q2055 claims analytics on FocalPoint →
OnPoint Oncology

Abecma CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
Not on the CMS JW / JZ list

CMS does not include Abecma (Q2055) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q2055. Wastage billing guide →

Abecma Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Relapsed or refractory multiple myeloma (after ≥2 prior lines including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody)

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.
Access Full Report →

Frequently Asked Questions

Is there an available Abecma billing and coding guide?
Billing and coding information for Abecma can be found through Celgene. Visit Here →
Are there any available Abecma patient assistance programs?
Abecma patient assistance information can be found through Celgene. Visit Here →
Where can I find Abecma prescribing information?
Abecma prescribing information can be found at the link below: Visit Here →
Where can I find Abecma side effect information?
Information regarding Abecma's side effects can be found at MedlinePlus Visit Here →
Does billing Abecma require JZ/JW wastage modifiers?
CMS does not include Abecma (Q2055) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q2055. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.

Related Drug Codes

Explore billing, coding, and pricing for drugs related to Abecma.

C9142AlymsysInjection, bevacizumab-maly, biosimilar, (alymsys), 10 mgAmneal BiosciencesAdded October 1, 2022C9146ELAHEREInjection, mirvetuximab soravtansine-gynx, 1 mgImmunogenAdded April 1, 2023C9147IMJUDOInjection, tremelimumab-actl, 1 mgAstrazenecaAdded April 1, 2023C9148TECVAYLIInjection, teclistamab-cqyv, 0.5 mgJanssenAdded April 1, 2023C9155EPKINLYInjection, epcoritamab-bysp, 0.16 mgGenmabAdded October 1, 2023C9163TALVEYInjection, talquetamab-tgvs, 0.25 mgJanssenAdded January 1, 2024C9165ELREXFIOInjection, elranatamab-bcmm, 1 mgPfizerAdded January 1, 2024C9169ANKTIVAInjection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgramAltor BioScience, LLCAdded October 1, 2024C9170IMDELLTRAInjection, tarlatamab-dlle, 1 mgAmgenAdded October 1, 2024C9173NYPOZIInjection, filgrastim-txid (nypozi), biosimilar, 1 microgramTanvex Biopharma USAAdded January 1, 2025